Navigation Links
Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
Date:9/11/2007

- Additional Phase 3 Trials on Track for Initiation Later This Year -

- Conference Call Scheduled for Today at 8:30 a.m. Eastern Time -

SAN DIEGO, Sept. 11 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that an independent Echocardiographic Data Safety Monitoring Board (the Board or EDSMB) found no reason to stop the ongoing pivotal Phase 3 trial, BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management). The BLOOM trial is evaluating the efficacy and safety of lorcaserin hydrochloride for the treatment of obesity. The findings of the Board were based on a planned detailed review of unblinded echocardiograms performed after patients completed six months of dosing in the trial. The review was conducted by the Board and confirms that differences, if any, in the rates of U.S. Food and Drug Administration (FDA)-defined valvulopathy in patients treated with lorcaserin and in the control group did not meet predetermined stopping criteria. The review also confirmed that the rate of FDA-defined valvulopathy in the placebo group is consistent with the company's statistical powering assumptions used in the design of the pivotal trial program to monitor patients for any increased risk of developing valvulopathy. Arena is currently in discussions with the FDA to finalize protocols for two additional Phase 3 pivotal trials scheduled to begin later this year.

"Patient safety is and always has been a primary focus for Arena in our effort to fully explore and understand lorcaserin's profile and its potential to safely help a significant number of patients that are obese or overweight improve their health by better managing their weight," said Jack Lie
'/>"/>

SOURCE Arena Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Traveling stem cell show continues state tour
4. AT&T - BellSouth merger: Revestiture continues
5. Madison biotech continues its climb
6. Brady continues growth through Asian acquisition
7. Transition continues to impact Third Wave financials
8. Line between big pharma, big biotech continues to blur
9. Wisconsin giant continues to dominate the health care IT market
10. API Software continues expansion
11. Third Wave continues molecular diagnostic focus with new CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... PharmaBoardroom,s new report, , Healthcare and ... free download , digs deep into this vibrant market, ... sector today. One area where Algeria ... a homegrown pharmaceutical manufacturing base, even if the government,s ambitious ... off. A cursory comparison with neighboring Morocco ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 The ... global leader of technical training across the life sciences ... Data Management (SCDM) to provide the organization's members ... programs —providing access to the more than 350 sessions ... members with 10% off when registering for a ...
(Date:12/22/2014)... , Dec. 22, 2014 GenomeDx Biosciences today ... Prostate Cancer Classifier, a genomic test for prostate cancer, ... high-risk men managed by radical prostatectomy without adjuvant therapy. ... is relatively uncommon, using tumor genomics to identify these ... disease is an important advance. The study has been ...
(Date:12/22/2014)... Fertility Associates of Memphis has announced ... , a network of more than 20 contributing ... have fast access to a national pool of frozen ... Fertility Associates of Memphis is the only fertility clinic ... , Dr. William Kutteh , director of Fertility ...
Breaking Biology Technology:PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3
... 2 Sanofi-aventis announced,today that one year ... STEEPLE,studies confirm clear net clinical benefit for ... for Lovenox(R) vs,Unfractionnated Heparin (UFH). The ... were presented during,hotline sessions at the European ...
... Researchers at the National Institute of Standards ... calibration tools to help correct and validate ... substances based on fluorescence. , Recent ... the development and use of fluorescence-based analytic ...
... governments biodefense efforts, the potential for terrorists to cause ... years after the letter attacks that shook the nation ... University of Michigan Medical School have developed the first ... inside unwitting immune cells their supposed attackers ...
Cached Biology Technology:New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 2New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 3New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 4New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 5Fluorescent glass SRMs are new tool for spectroscopy 2Taming the anthrax threat 2Taming the anthrax threat 3
(Date:12/22/2014)... DUBLIN , Dec. 22, 2014 /PRNewswire/ ... ) has announced the addition of the ... report to their offering. ... This insight provides an overview of the ... Watermarking aims to control and monitor piracy ...
(Date:12/19/2014)... Research and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... July 2012, Apple introduced the fingerprint reading feature ... only device of Apple incorporating such a feature, ...
(Date:12/19/2014)... Calif. , Dec. 18, 2014  23andMe, Inc., ... of a study that pinpoints fine-scale differences in genetic ... States . Since immigrants first arrived ... United States has served as a meeting ... how American history and the ongoing mixing of peoples ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... living sensor that can spot contamination. They have also ... even in previously untreatable cold areas, microbiologists heard today ... Microbiology,s Autumn meeting being held this week at Trinity ... in the sub-arctic. It contains over 230,000 tonnes of ...
... a new method to fabricate borosilicate glass ... nanoparticles are more stable when subjected to ... currently used nanoparticles made of polymers or ... range of potential nanoparticle applications in biomedical, ...
... MD The Biophysical Society is pleased to announce ... recipients will receive their awards at the Society,s 53rd ... Boston Convention and Exhibitions Center in Massachusetts. The awardees ... California, San Francisco, will receive the Anatrace Membrane Protein ...
Cached Biology News:Living sensor can warn of arsenic pollution 2Biophysical Society names 2009 award recipients 2